International Myeloma Society Educational Workshop – Belgrade, Serbia 2026 (Videos)

Comprehensive Updates in Multiple Myeloma, Plasma Cell Disorders, MRD Testing, CAR T-Cell Therapy, Bispecific Antibodies, AL Amyloidosis, Waldenström Macroglobulinemia, and Precision Hematologic Oncology

Stay at the forefront of plasma cell malignancy management with the International Myeloma Society Educational Workshop – Belgrade, Serbia 2026, a world-class continuing medical education (CME) event organized by the International Myeloma Society (IMS) in collaboration with the Balkan Myeloma Study Group and the Serbian Myeloma Group. This highly specialized educational workshop brings together internationally recognized experts to present the latest scientific advances, evidence-based treatment strategies, and emerging therapeutic innovations in multiple myeloma and related plasma cell disorders.

Held March 13–14, 2026, in Belgrade, Serbia, the workshop features expert lectures, multidisciplinary roundtable discussions, point-counterpoint debates, and challenging clinical case reviews designed to address the most important developments in diagnostic evaluation, risk stratification, measurable residual disease (MRD), immunotherapy, cellular therapy, supportive care, and personalized treatment planning.

Designed for hematologists and oncologists managing patients with plasma cell malignancies, this comprehensive program provides practical guidance on integrating rapidly evolving therapies—including CAR T-cell therapy, Bispecific T-cell Engagers (BiTEs), novel immunotherapies, and precision medicine—into everyday clinical practice.

Product Details

• Course: International Myeloma Society Educational Workshop – Belgrade, Serbia 2026
• Provider: International Myeloma Society (IMS)
• Collaborating Organizations: Balkan Myeloma Study Group & Serbian Myeloma Group
• Conference Dates: March 13–14, 2026
• Location: Belgrade, Serbia
• Format: Videos
• Language: English
• Educational Level: Advanced
• Learning Format: Expert Lectures, Roundtable Discussions, Point-Counterpoint Sessions, Clinical Case Reviews

Course Overview

The treatment landscape for Multiple Myeloma has evolved dramatically with advances in molecular diagnostics, measurable residual disease (MRD) assessment, immunotherapy, cellular therapies, targeted agents, and personalized treatment strategies. Clinicians must continually adapt to emerging evidence regarding disease biology, risk stratification, sequencing of therapies, and management of increasingly complex clinical scenarios.

The International Myeloma Society Educational Workshop 2026 provides a comprehensive review of contemporary plasma cell malignancy management. International leaders in hematology discuss updated diagnostic criteria, advanced imaging, transplant decision-making, novel immunotherapies, relapse management, supportive care, and evolving treatment algorithms for patients across every stage of multiple myeloma.

Special emphasis is placed on integrating MRD-guided treatment, CAR T-cell therapy, bispecific antibodies, frailty assessment, supportive care, and multidisciplinary management to improve survival, quality of life, and long-term patient outcomes.

What You'll Learn

After completing this course, participants will be able to:

• Apply updated diagnostic criteria and imaging techniques for multiple myeloma.
• Integrate measurable residual disease (MRD) testing into treatment planning.
• Utilize contemporary risk stratification models for smoldering and newly diagnosed multiple myeloma.
• Develop evidence-based treatment strategies for transplant-eligible and transplant-ineligible patients.
• Optimize sequencing of therapies for relapsed and refractory multiple myeloma.
• Incorporate CAR T-cell therapy and bispecific antibodies into clinical practice.
• Manage complications including bone disease, renal impairment, infections, and treatment-related toxicities.
• Diagnose and treat related plasma cell disorders including AL amyloidosis and Waldenström macroglobulinemia.

Comprehensive Topics Covered

Multiple Myeloma Diagnosis

Strengthen diagnostic accuracy using current international standards.

Topics include:

• Multiple myeloma diagnosis
• Laboratory evaluation
• Bone marrow assessment
• Cytogenetics
• Advanced imaging
• Disease staging
• Diagnostic criteria

Faculty review the latest recommendations for early diagnosis and comprehensive disease evaluation.

Measurable Residual Disease (MRD)

Integrate MRD assessment into precision treatment planning.

Topics include:

• Measurable residual disease (MRD)
• MRD testing
• Flow cytometry
• Next-generation sequencing
• Response assessment
• Prognostic value
• Treatment monitoring

Risk Stratification

Improve individualized treatment selection.

Topics include:

• High-risk myeloma
• Cytogenetic abnormalities
• Molecular profiling
• Risk-adapted therapy
• Prognostic biomarkers
• Personalized medicine
• Clinical decision-making

Smoldering Multiple Myeloma

Review current management strategies for early disease.

Topics include:

• Smoldering myeloma
• Disease progression
• Early intervention
• Observation strategies
• Risk prediction
• Clinical trials
• Preventive treatment

Newly Diagnosed Multiple Myeloma

Master evidence-based frontline therapy.

Topics include:

• Newly diagnosed multiple myeloma
• Induction therapy
• Stem cell transplantation
• Maintenance therapy
• Transplant eligibility
• Non-transplant management
• First-line treatment

Faculty discuss individualized treatment pathways based on patient characteristics and disease biology.

Relapsed & Refractory Multiple Myeloma

Optimize sequencing of increasingly complex therapies.

Topics include:

• Relapsed multiple myeloma
• Refractory disease
• Treatment sequencing
• Triple-class refractory disease
• Salvage therapy
• Clinical decision-making
• Emerging agents

Cellular & Immune Therapies

Explore revolutionary advances in immunotherapy.

Topics include:

• CAR T-cell therapy
• Bispecific T-cell Engagers (BiTEs)
• Immune-based therapy
• Cellular immunotherapy
• T-cell redirection
• Immune toxicity
• Novel immunotherapeutics

Participants review patient selection, efficacy, toxicity management, and future directions.

Supportive Care

Improve quality of life through comprehensive supportive management.

Topics include:

• Bone disease
• Bisphosphonates
• Renal failure
• Infection prevention
• Vaccination
• Supportive oncology
• Symptom management

Plasma Cell Disorders Beyond Multiple Myeloma

Expand expertise in related hematologic diseases.

Topics include:

• Waldenström macroglobulinemia
• AL amyloidosis
• Monoclonal gammopathies
• Plasma cell dyscrasias
• Rare plasma cell disorders
• Disease-specific management
• Emerging therapies

Challenging Clinical Scenarios

Address complex cases encountered in modern practice.

Topics include:

• Extramedullary disease
• Relapse after CAR T-cell therapy
• Post-bispecific relapse
• Frailty assessment
• Elderly patients
• Personalized treatment algorithms
• Difficult clinical cases

Emerging Research & Future Therapies

Review innovations shaping the future of myeloma care.

Topics include:

• Novel targeted therapies
• Precision oncology
• Clinical trials
• Next-generation immunotherapy
• Combination strategies
• Future treatment paradigms
• Translational research

Learning Objectives

Upon completion of this educational activity, participants will be able to:

• Implement updated diagnostic testing, imaging techniques, and measurable residual disease (MRD) assessment for multiple myeloma.
• Apply contemporary risk stratification models for smoldering and newly diagnosed multiple myeloma.
• Develop evidence-based treatment strategies for transplant-eligible and transplant-ineligible patients.
• Optimize sequencing of therapies for relapsed and refractory multiple myeloma.
• Incorporate novel immunotherapies including CAR T-cell therapy and bispecific T-cell engagers into clinical practice.
• Manage myeloma-related complications including bone disease, renal impairment, infections, and supportive care needs.
• Diagnose and manage AL amyloidosis, Waldenström macroglobulinemia, and other plasma cell disorders.
• Address challenging clinical situations including relapse after T-cell–redirected therapies, extramedullary disease, and frailty-based treatment decisions.

Educational Highlights

• Multiple Myeloma
• Plasma Cell Disorders
• Measurable Residual Disease (MRD)
• CAR T-Cell Therapy
• Bispecific Antibodies
• Immunotherapy
• Stem Cell Transplantation
• Relapsed & Refractory Multiple Myeloma
• Smoldering Multiple Myeloma
• Risk Stratification
• Precision Hematology
• Waldenström Macroglobulinemia
• AL Amyloidosis
• Bone Disease
• Supportive Oncology
• Hematologic Malignancies
• Plasma Cell Dyscrasias
• Cellular Therapy
• Hematologic Oncology
• Continuing Medical Education (CME)

Why This Course Stands Out

The International Myeloma Society Educational Workshop – Belgrade 2026 is one of the premier international educational events dedicated exclusively to plasma cell malignancies. Led by globally recognized experts from the International Myeloma Society, the workshop delivers cutting-edge updates on disease biology, MRD-guided therapy, advanced immunotherapies, cellular treatments, supportive care, and personalized treatment sequencing. Its interactive debates, multidisciplinary discussions, and complex clinical case reviews provide participants with practical strategies that can immediately enhance patient care in modern hematologic oncology.

Target Audience

This educational activity is ideal for:

• Hematologists
• Medical Oncologists
• Hematologic Oncologists
• Bone Marrow Transplant Physicians
• Cellular Therapy Specialists
• Clinical Hematology Fellows
• Medical Oncology Fellows
• Internal Medicine Physicians with Hematology Interest
• Oncology Pharmacists
• Oncology Nurse Practitioners
• Physician Assistants specializing in Hematology/Oncology
• Clinical Researchers
• Healthcare Professionals involved in the diagnosis and treatment of plasma cell malignancies

Why Choose This Course?

Whether you specialize in hematology, medical oncology, bone marrow transplantation, or cellular therapy, the International Myeloma Society Educational Workshop 2026 provides one of the most comprehensive and up-to-date educational experiences in multiple myeloma and plasma cell disorders. Through internationally recognized faculty, evidence-based lectures, interactive debates, and challenging case discussions, participants gain the expertise needed to integrate novel immunotherapies, optimize treatment sequencing, improve supportive care, and deliver precision medicine for patients with plasma cell malignancies.

Topics

• Plenary Talks:

  • From Biology to Therapy: The Current Landscape of Multiple Myeloma.

  • The Future of Multiple Myeloma.

• Diagnosis, Risk Stratification, and Monitoring of Plasma Cell Disorders:

  • Diagnostic Testing for Multiple Myeloma, Risk Stratification and Follow-up.

  • Update and Recommendations on Imaging Techniques in Myeloma.

  • MRD Testing in Multiple Myeloma.

  • New Risk Stratification in Smoldering and Multiple Myeloma.

  • Live Panel Discussion: Diagnosis and Follow Up of Patients.

• Smoldering MM and Newly Diagnosed Multiple Myeloma:

  • Management of Clinical Significance/Smoldering Myeloma.

  • Management of Newly Diagnosed MM Transplant Eligible.

  • Management of Newly Diagnosed MM Non-transplant Eligible.

  • Live Panel Discussion: How to Manage SMM and NDMM.

• Relapsed and Refractory Multiple Myeloma:

  • Optimal Sequencing for RRMM Patients in their 1st and 2nd Relapse.

  • Novel Treatments for MM Besides Cell Therapies and Bispecifics.

  • Live Panel Discussion: Sequencing of Therapies in RR MM.

• Novel Immune Strategies:

  • CAR T Cells.

  • Bispecific T Cell Engagers.

  • Live Panel Discussion: Incorporating Novel Immunotherapies in Practice.

• Supportive Care:

  • Bone Disease and Renal Failure.

  • Infection and Vaccinations.

  • Live Panel Discussion: Managing Myeloma Related Complications.

• Update on Other Plasma Cell Disorders:

  • Waldenström’s Macroglobulinemia.

  • AL Amyloidosis.

  • Live Panel Discussion: Managing Other Dysporteinemias.

• Challenging Questions in MM:

  • Relapse After T Cell Redirected Therapies.

  • Extramedullary Disease and Plasma Cell Leukemia.

  • Incorporating Frailty into Treatment Algorithms for MM.

  • Live Panel Discussion.